📊 FEMY Key Takeaways
Is Femasys Inc. (FEMY) a Good Investment?
Femasys exhibits severe financial distress with massive operating losses (-$13.0M on $1.5M revenue) and deeply negative cash flow (-$14.9M), indicating the company is burning cash at an unsustainable rate. Despite 52% revenue growth, the company lacks profitability at every level and is operating far from cash flow breakeven, with only 4.6 months of cash runway at current burn rates. The negative gross margin contribution to fixed costs and complete absence of path to profitability present extreme risk of capital insufficiency.
Femasys shows early revenue growth, but the absolute scale of the business remains far too small relative to its operating cost structure. Losses are extreme versus revenue, cash burn is heavy, and liquidity is only marginal, which makes the current growth profile low quality and financially fragile. The debt-free balance sheet helps, but fundamentals still point to a business that likely needs substantial operating improvement or external capital to sustain itself.
Why Buy Femasys Inc. Stock? FEMY Key Strengths
- Revenue growing 52% year-over-year showing market traction for products
- Positive gross margin of 37.6% indicates underlying product economics are viable
- No long-term debt providing some balance sheet flexibility and avoiding interest burden
- Revenue grew 52.0% year over year, indicating some commercial traction
- The company has no meaningful long-term debt, reducing balance sheet leverage risk
- Cash roughly matches stockholders' equity, providing some near-term operating flexibility
FEMY Stock Risks: Femasys Inc. Investment Risks
- Catastrophic operating losses of -$13.0M against only $1.5M revenue indicating massive operating expense structure misalignment
- Severely negative free cash flow of -$14.9M with only $4.6M cash equivalents, suggesting approximately 3.7 months of runway at current burn rate
- Net margin of -991.8% and operating margin of -876.1% indicate company is nowhere near unit economics breakeven despite revenue growth
- Negative interest coverage of -35.9x reflects inability to service any debt obligations
- Rapid cash depletion threatens ability to fund operations and R&D within 12 months without capital raise or dramatic expense reduction
- Operating and net margins are deeply negative, showing the business model is not close to breakeven
- Free cash flow and operating cash flow are severely negative, implying continued cash consumption
- Liquidity is weak with a 1.16x current ratio and 0.61x quick ratio, raising funding risk if burn continues
Key Metrics to Watch
- Operating cash flow trajectory and time to cash depletion at current burn rate
- Quarterly revenue growth sustainability and gross margin consistency
- Operating expense reduction initiatives and path to operating breakeven
- Cash balance and timing of any equity raises or financing events
- Customer acquisition cost relative to lifetime value and unit economics
- Capital expenditure requirements for manufacturing scaling
- Quarterly revenue growth versus operating expense growth
- Cash runway and improvement in operating cash flow/free cash flow
Femasys Inc. (FEMY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Femasys Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
FEMY Profit Margin, ROE & Profitability Analysis
FEMY vs Healthcare Sector: How Femasys Inc. Compares
How Femasys Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Femasys Inc. Stock Overvalued? FEMY Valuation Analysis 2026
Based on fundamental analysis, Femasys Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Femasys Inc. Balance Sheet: FEMY Debt, Cash & Liquidity
FEMY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Femasys Inc.'s revenue has grown significantly by 94% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.85 indicates the company is currently unprofitable.
FEMY Revenue Growth, EPS Growth & YoY Performance
FEMY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $554.9K | -$4.2M | $-0.10 |
| Q2 2025 | $221.5K | -$4.6M | $-0.16 |
| Q1 2025 | $271.1K | -$3.6M | $-0.17 |
| Q3 2024 | $244.4K | -$4.0M | $-0.24 |
| Q2 2024 | $221.5K | -$2.9M | $-0.21 |
| Q1 2024 | $271.1K | -$2.9M | $-0.17 |
| Q3 2023 | $244.4K | -$3.0M | $-0.25 |
| Q2 2023 | $303.1K | -$2.6M | $-0.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Femasys Inc. Dividends, Buybacks & Capital Allocation
FEMY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Femasys Inc. (CIK: 0001339005)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FEMY
What is the AI rating for FEMY?
Femasys Inc. (FEMY) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FEMY's key strengths?
Claude: Revenue growing 52% year-over-year showing market traction for products. Positive gross margin of 37.6% indicates underlying product economics are viable. ChatGPT: Revenue grew 52.0% year over year, indicating some commercial traction. The company has no meaningful long-term debt, reducing balance sheet leverage risk.
What are the risks of investing in FEMY?
Claude: Catastrophic operating losses of -$13.0M against only $1.5M revenue indicating massive operating expense structure misalignment. Severely negative free cash flow of -$14.9M with only $4.6M cash equivalents, suggesting approximately 3.7 months of runway at current burn rate. ChatGPT: Operating and net margins are deeply negative, showing the business model is not close to breakeven. Free cash flow and operating cash flow are severely negative, implying continued cash consumption.
What is FEMY's revenue and growth?
Femasys Inc. reported revenue of $1.5M.
Does FEMY pay dividends?
Femasys Inc. does not currently pay dividends.
Where can I find FEMY SEC filings?
Official SEC filings for Femasys Inc. (CIK: 0001339005) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FEMY's EPS?
Femasys Inc. has a diluted EPS of $-0.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FEMY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Femasys Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FEMY stock overvalued or undervalued?
Valuation metrics for FEMY: ROE of -322.1% (sector avg: 15%), net margin of -991.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FEMY stock in 2026?
Our dual AI analysis gives Femasys Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FEMY's free cash flow?
Femasys Inc.'s operating cash flow is $-14.5M, with capital expenditures of $385.2K. FCF margin is -1,006.2%.
How does FEMY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -991.8% (avg: 12%), ROE -322.1% (avg: 15%), current ratio 1.16 (avg: 2).